Drug intelligence / Profile preview

rMAGE-3

Development stage
Unknown
Lead developer
GSK
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

rMAGE-3 is a recombinant protein-based therapeutic vaccine candidate targeting the melanoma-associated antigen 3 (MAGE-A3), which is expressed in various tumors but not in normal tissues except for testis and placenta. The drug is designed to stimulate an immune response against cancer cells expressing the MAGE-A3 antigen. It has been investigated primarily as an immunotherapy for cancers such as melanoma and non-small cell lung cancer. The mechanism of action involves presenting the MAGE-A3 antigen to the immune system, thereby inducing cytotoxic T lymphocyte responses that target and destroy tumor cells expressing this antigen.

Other names
recombinant MAGE-A3 proteinMAGE-A3 proteinMAGE-A-3 proteinMAGE-A 3 proteinrecombinant melanoma-associated antigen 3
02

Targets

MAGEA3 (Melanoma-associated antigen 3)

Beyond the preview

Go deeper on rMAGE-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rMAGE-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call